Approval · Notice of Compliance 34945 · 2025
JAMP ALMOTRIPTAN: Notice of Compliance 34945
Issued March 5, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34945
- Date
- March 5, 2025
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- MYLAN-ALMOTRIPTAN (Mylan Pharmaceuticals Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP ALMOTRIPTAN | 02556022 | Approved |
| JAMP ALMOTRIPTAN | 02556030 | Approved |
Medicinal ingredients
- ALMOTRIPTAN MALATE 6.25 MG per TAB
- ALMOTRIPTAN MALATE 12.5 MG per TAB